Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder

NCT00745966 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2008-10-06

No results posted yet for this study

Summary

The purpose of this study is to reassure the clinical study data on atypical antipsychotics effect on quality of life in Korean Bipolar patients.

Conditions

  • Naturalistic
  • Observational

Sponsors & Collaborators

Principal Investigators

  • Joon-Woo Bahn · Astrazeneca, Korea

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2008-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00745966 on ClinicalTrials.gov